Celcuity (CELC) Times Interest Earned (2017 - 2026)
Celcuity's (CELC) quarterly Times Interest Earned came in at -$16.81 in Q4 2025, down 51.11% YoY from -$34.38 in Q4 2024, and down 7157.54% on a QoQ basis from -$0.23 in Q3 2025.
Powered by 
Analysis
Celcuity (CELC) Times Interest Earned (2017 - 2026) Analysis & Trends
Celcuity (CELC) has 9 years of Times Interest Earned data on file, last reported at -$16.81 in Q4 2025.
- Quarterly Times Interest Earned fell 51.11% year-over-year to -$16.81 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$22.98 (up 9.99% YoY) and the FY2025 annual result came in at -$0.37, up 80.45% from the prior year.
- Times Interest Earned declined to -$16.81 in Q4 2025, from -$0.23 in the prior quarter.
- In the past five years, Times Interest Earned ranged from a high of $48.71 in Q4 2021 to a low of -$27.51 in Q4 2022.
- A 5-year average of -$2.82 and a median of -$1.61 in 2023 frame the typical range for Times Interest Earned.
- Annual changes were most pronounced in 2021 — Times Interest Earned soared 100.05% — and 2025, when it plunged 812.89%.
- Tracing CELC's Times Interest Earned over 5 years: stood at $48.71 in 2021, then tumbled by 156.47% to -$27.51 in 2022, then increased by 17.43% to -$22.71 in 2023, then jumped by 51.03% to -$11.12 in 2024, then slumped by 51.11% to -$16.81 in 2025.
- The last three Times Interest Earned figures came in at -$16.81 (Q4 2025), -$0.23 (Q3 2025), and -$2.47 (Q2 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Times Interest Earned (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 117.59 |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | -493.00 |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -21.24 |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 8.18 |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 2.82 |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 1.42 |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -0.08 |
| 10 | Celcuity | 5.25 Bn | 5.25 Bn | - | -12.19 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -12.19 |
| Dec 31, 2025 | -7.98 |
| Sep 30, 2025 | -9.33 |
| Jun 30, 2025 | -13.74 |
| Mar 31, 2025 | -11.35 |
| Dec 31, 2024 | -11.12 |
| Sep 30, 2024 | -8.99 |
| Jun 30, 2024 | -10.75 |
| Mar 31, 2024 | -16.05 |
| Dec 31, 2023 | -14.12 |
| Sep 30, 2023 | -13.77 |
| Jun 30, 2023 | -11.45 |
| Mar 31, 2023 | -10.10 |
| Dec 31, 2022 | -17.17 |
| Sep 30, 2022 | -19.80 |
| Jun 30, 2022 | -21.08 |
| Mar 31, 2022 | -17.26 |
| Dec 31, 2021 | -14.43 |
| Sep 30, 2021 | -12.93 |
| Jun 30, 2021 | -34.88 |